Literature DB >> 10203486

Discrimination of subtype B and non-subtype B strains of human immunodeficiency virus type 1 by serotyping: correlation with genotyping.

G Murphy1, F J Belda, C P Pau, J P Clewley, J V Parry.   

Abstract

The ability of a peptide-based serotyping assay to differentiate human immunodeficiency virus (HIV) type 1 (HIV-1) subtype B infections from non-subtype B infections was investigated with 166 anti-HIV-1- and HIV RNA-positive (by PCR) serum or plasma specimens. The specimens were divided genetically into those infected with subtype B and non-subtype B by application of a screening heteroduplex mobility assay (HMA) that used plasmids for subtypes A and B alone. Specimens that were not clearly infected with HIV-1 subtype B by HMA or for which the two methods had discordant results in distinguishing those infected with subtype B from those infected with non-subtype B were then investigated with a full HMA plasmid panel and, for selected specimens, env sequencing. For the 141 genotyped and serotypically reactive specimens, the correlation between genotyping and serotyping (all subtypes) was 69%. Of the 67 specimens that reacted monotypically as serotype B, 64 were shown to be infected with genotype B (positive predictive value, 96%). Of the 82 specimens that contained genotype B nucleic acid, 64 reacted monotypically as serotype B (sensitivity, 78%), and 4 specimens reacted with a single non-subtype B peptide; the viruses in 14 specimens could not be assigned a serotype. Initial screening results had indicated that 12 samples had results discordant between restricted HMA and serotyping. The V3 loop amino acids of the infecting HIV strains from the seven specimens with discordant serology results were analyzed. For five specimens discordance occurred when the amino acid sequence of the infecting virus closely resembled those of more than one consensus peptide antigen or when the observed V3 crown motif of the strain was atypical for the genetic subtype present. For the other two specimens no explanation for the discordance was identified. Five specimens gave unclear or discordant results in the initial HMA screen, but the results were resolved when the full plasmid panel was used. Serotyping, although of limited sensitivity, distinguishes between subtype B and non-subtype B infections with a high degree of specificity. However, it poorly differentiates the major non-subtype B subtypes, particularly subtypes A and C. When HIV-1 subtype B predominates, serological typing and/or subtype-restricted HMA screening usefully distinguishes between subtype B and non-subtype B infections.

Entities:  

Mesh:

Year:  1999        PMID: 10203486      PMCID: PMC84775     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

2.  Detection of HIV-1 in serum, using reverse transcription and the polymerase chain reaction (RT-PCR).

Authors:  K M Gibson; J Mori; J P Clewley
Journal:  J Virol Methods       Date:  1993-06       Impact factor: 2.014

3.  Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays.

Authors:  J P Moore; Y Cao; A J Conley; R Wyatt; J Robinson; M K Gorny; S Zolla-Pazner; D D Ho; R A Koup
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-04

4.  A dual subtype B/E HIV type 1 infection with a novel V3 loop crown motif among infections acquired in Thailand and imported into England.

Authors:  F J Belda; K L Barlow; G Murphy; J V Parry; J P Clewley
Journal:  AIDS Res Hum Retroviruses       Date:  1998-07-01       Impact factor: 2.205

5.  Sensitivity of screening kits for anti-HIV-1 subtype O antibodies.

Authors:  F Simon; T D Ly; A Baillou-Beaufils; V Fauveau; J De Saint-Martin; I Loussert-Ajaka; M L Chaix; S Saragosti; A M Courouce; D Ingrand
Journal:  AIDS       Date:  1994-11       Impact factor: 4.177

6.  Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites. WHO Network for HIV Isolation and Characterization.

Authors:  C P Pau; M Kai; D L Holloman-Candal; C C Luo; M L Kalish; G Schochetman; B Byers; J R George
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

7.  Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization.

Authors:  R Cheingsong-Popov; S Lister; D Callow; P Kaleebu; S Beddows; J Weber
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

8.  Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections.

Authors:  C Schable; L Zekeng; C P Pau; D Hu; L Kaptue; L Gurtler; T Dondero; J M Tsague; G Schochetman; H Jaffe
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

9.  Rapid grouping of HIV-1 infection in subtypes A to E by V3 peptide serotyping and its relation to sequence analysis.

Authors:  K Sherefa; A Sönnerborg; J Steinbergs; M Sällberg
Journal:  Biochem Biophys Res Commun       Date:  1994-12-30       Impact factor: 3.575

10.  Polymerase chain reaction and sequencing for typing rhinovirus RNA.

Authors:  J Mori; J P Clewley
Journal:  J Med Virol       Date:  1994-12       Impact factor: 2.327

View more
  5 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Authors:  Philippa J Easterbrook; Mel Smith; Jane Mullen; Siobhan O'Shea; Ian Chrystie; Annemiek de Ruiter; Iain D Tatt; Anna Maria Geretti; Mark Zuckerman
Journal:  J Int AIDS Soc       Date:  2010-02-03       Impact factor: 5.396

3.  Use of a heteroduplex mobility assay to detect differences in the fusion protein cleavage site coding sequence among Newcastle disease virus isolates.

Authors:  A Berinstein; H S Sellers; D J King; B S Seal
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

4.  Determination of human immunodeficiency virus type 1 subtypes by a rapid method useful for the routine diagnostic laboratory.

Authors:  H H Kessler; D Deuretzbacher; E Stelzl; E Daghofer; B I Santner; E Marth
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 5.  Identifying HIV-1 dual infections.

Authors:  Antoinette C van der Kuyl; Marion Cornelissen
Journal:  Retrovirology       Date:  2007-09-24       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.